Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
DexCom, Inc. logo

NASDAQ · DXCM

DexCom, Inc.

Healthcare · Medical - Devices

$84.11

Down-$0.30 (-0.36%)

Updated Oct 11, 2026, 4:31 AM

SID Score

6.6/10

Composite research score

Smart Money

48/100

Neutral

Market cap
26.96B
P/E ratio
37.41
Dividend yield
0.00%
52-week range
$56.72 – $92.59
Volume
3.15M
Avg. volume
6.48M

Price performance · DXCM

DXCM price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

DXCM closed at $84.11 after 20 trading sessions, down 0.67% for the selected period.

Last close
$84.11
Period change
-0.67%
Period low
$83.39
Period high
$89.53
Daily close
View OHLC price history
DXCM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$84.41$85.49$82.935$84.113.15M
Oct 8, 2026$84.01$84.54$83.075$84.413.61M
Oct 7, 2026$83.805$85.695$83.74$84.302.86M
Oct 6, 2026$86.28$86.75$82.86$83.393.57M
Oct 5, 2026$84.75$87.12$84.75$86.903.08M
Oct 2, 2026$86.665$86.665$84.80$85.362.2M
Oct 1, 2026$86.46$87.70$85.805$86.233.03M
Sep 30, 2026$86.21$86.75$85.255$86.293.47M
Sep 29, 2026$86.63$87.03$85.24$86.643.12M
Sep 28, 2026$86.87$87.34$85.27$86.683.41M
Sep 25, 2026$87.38$87.64$86.36$86.621.89M
Sep 24, 2026$87.675$88.00$86.88$87.472.14M
Sep 23, 2026$89.50$90.045$87.36$87.733.67M
Sep 22, 2026$89.12$90.385$88.18$89.537.3M
Sep 21, 2026$88.83$89.68$88.33$89.173.52M
Sep 18, 2026$87.825$89.92$87.39$89.3514.58M
Sep 17, 2026$87.54$88.26$87.17$87.932.82M
Sep 16, 2026$86.05$88.79$86.05$87.343.62M
Sep 15, 2026$84.04$87.36$83.255$86.455.96M
Sep 14, 2026$83.92$84.98$83.76$84.682.54M

Latest DXCM news

The latest Smart Investors Daily articles mentioning DXCM.

Stock researchCompany · Overview

DXCM research

Overview

Company profile and research snapshot.

Company profile

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$85.22
Implied upside
—
Analysts
37
DXCM recent ratings
DateFirmRatingTarget
Oct 7, 2026BarclaysOverweight—
Oct 1, 2026RBC CapitalOutperform—
Sep 18, 2026TD CowenBuy—
Sep 18, 2026Truist SecuritiesBuy—
Aug 4, 2026Argus ResearchBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

SAN DIEGO, October 07, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and wil

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By